SCHEMBL7010966

SCHEMBL7010966

CCCc1scc(Br)c1Br

nearest known ligand 0.39

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ADRA1D P25100 2/20 0.39
GSK3B P49841 2/20 0.33
GPR35 Q9HC97 4/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31379068 0.80
SCHEMBL7014325 0.74 GPR35 (0.33) GPR35
SCHEMBL7005086 0.73 LMNA (0.37)
SCHEMBL7005875 0.71
SCHEMBL13510846 0.70
SCHEMBL7005868 0.68
SCHEMBL8557305 0.65 HMGCR (0.31)
SCHEMBL9903007 0.64
SCHEMBL2600221 0.62
SCHEMBL8836866 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022101171-A1 SULFUROUS COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES MERCK PATENT GMBH (DE) 2022-05-19 WO disclosed
EP-0690863-B1 TETRACYCLIC COMPOUNDS AS DOPAMINE AGONISTS ABBOTT LAB (US) 2003-03-05 EP disclosed
US-5597832-A TREATMENT OF NEUROLOGICAL, PSYCHOLOGICAL, CARDIOVASCULAR DISORDERS, AND SUBSTANCE ABUSE, BEHAVIOR DISORDERS, COGNITIVE IMPAIRMENT AND ATTENTION DEFICIT DISORDER ABBOTT LABORATORIES (US) 1997-01-28 US disclosed
EP-0690863-A1 TETRACYCLIC COMPOUNDS AS DOPAMINE AGONISTS ABBOTT LABORATORIES (US) 1996-01-10 EP disclosed
EP-0690863-A4 TETRACYCLIC COMPOUNDS AS DOPAMINE AGONISTS ABBOTT LAB (US) 1995-11-07 EP disclosed
WO-1994022858-A1 TETRACYCLIC COMPOUNDS AS DOPAMINE AGONISTS ABBOTT LABORATORIES (US) 1994-10-13 WO disclosed